PharmaGap Releases Compelling Results For GAP-107B8 From The U.S. National Cancer Institute

OTTAWA, ONTARIO -- PharmaGap Inc. ("PharmaGap" or "the Company") is pleased to announce results from the initial testing of its lead cancer drug GAP-107B8 by the U.S. National Cancer Institute (NCI). The NCI data clearly demonstrates significant inhibition of cancer cell growth at a low drug concentration (10 micronsM) across a wide range of human cancer cell lines that comprise the NCI-60 panel. As currently configured, the NCI-60 panel is comprised of 57 human cancer cell lines derived from 9 different cancers (breast, prostate, renal, ovarian, CNS, colon, lung, melanoma and leukemia). The Company is very pleased to report that in this test, GAP-107B8 demonstrated greater than 50% inhibition in cancer cell growth in 26...